A framework to identify gene expression profiles in a model of inflammation induced by lipopolysaccharide after treatment with thalidomide by Renata T Paiva et al.
Paiva et al. BMC Research Notes 2012, 5:292
http://www.biomedcentral.com/1756-0500/5/292RESEARCH ARTICLE Open AccessA framework to identify gene expression profiles
in a model of inflammation induced by
lipopolysaccharide after treatment with
thalidomide
Renata T Paiva1, Alessandra M Saliba2, Tatiana O Fulco3, Jorgenilce de Souza Sales3, Daniel Serra de Carvalho3,
Elizabeth P Sampaio3, Ulisses G Lopes4, Euzenir N Sarno3 and Flavio F Nobre1*Abstract
Background: Thalidomide is an anti-inflammatory and anti-angiogenic drug currently used for the treatment of
several diseases, including erythema nodosum leprosum, which occurs in patients with lepromatous leprosy. In this
research, we use DNA microarray analysis to identify the impact of thalidomide on gene expression responses in
human cells after lipopolysaccharide (LPS) stimulation. We employed a two-stage framework. Initially, we identified
1584 altered genes in response to LPS. Modulation of this set of genes was then analyzed in the LPS stimulated
cells treated with thalidomide.
Results: We identified 64 genes with altered expression induced by thalidomide using the rank product method. In
addition, the lists of up-regulated and down-regulated genes were investigated by means of bioinformatics
functional analysis, which allowed for the identification of biological processes affected by thalidomide.
Confirmatory analysis was done in five of the identified genes using real time PCR.
Conclusions: The results showed some genes that can further our understanding of the biological mechanisms in
the action of thalidomide. Of the five genes evaluated with real time PCR, three were down regulated and two
were up regulated confirming the initial results of the microarray analysis.
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Thalidomide, which was widely marketed as a safe seda-
tive and antiemetic for pregnant women between the
years 1958 and 1960, was implicated in the birth of
thousands of babies with congenital malformations in
the following years. In 1965, the drug changed its course
when it was showed to be effective in resolving symp-
toms associated with the inflammatory reaction of lep-
rosy known as erythema nodosum leprosum, or type II
reaction [1].
Currently, it is known that thalidomide is a drug
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reproduction in any medium, provided the orangiogenic properties and that it is the drug of choice
for the treatment of the type II leprosy reaction. Thal-
idomide is also used in some complications related to
AIDS (acquired immunodeficiency syndrome), multiple
myeloma, and chronic degenerative diseases, such as
systemic lupus erythematosus and graft-versus-host
disease [1-3]. Despite being approved for use in treat-
ing these diseases, and despite being used in experi-
mental treatments of dozens of other diseases, such as
heart failure and several types of solid tumors, the way
that thalidomide mediates its anti-angiogenic and anti-
inflammatory effects and the underlying molecular
mechanisms involved has not been fully understood
[4-6].
It has been demonstrated by several groups that thal-
idomide changes the levels of tumor necrosis factortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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logical processes such as programmed cell death (apop-
tosis) and immune response [7-9]. It is also believed that
the many biological activities associated with thalidomide
can be explained largely by its effects on the activity of
nuclear factor kappa B (NF-κB) [10]. NF-κB is a tran-
scription factor involved in many physiological processes.
These processes include the regulation of genes related
to inflammation, such as cytokines TNF, IL6 and IL2 pro-
teins, the regulation of genes involved in apoptosis, such
as baculoviral IAP repeat containing 3 (BIRC3) and fam-
ily members’ Bcl-2, and in angiogenic factors, e.g., vascu-
lar endothelial growth factor (VEGF) [11].
The lipopolysaccharide (LPS) is a complex glycolipidic
constituent of the outer cell wall of Gram-negative bac-
teria. LPS initiates its response through the stimulation
of host cells such as monocytes and macrophages to pro-
duce and release endogenous mediators, including the
pro-inflammatory cytokines IL-1, IL-6 and TNF [12].
MOREIRA et al. [13] examined the inhibitory action of
thalidomide on TNF production induced by lipopolysac-
charides and reported that the drug increases the degrad-
ation of TNF mRNA. The authors found that inhibition
of TNF production was selective without changing other
cytokines induced by LPS. The referred selective inhib-
ition of TNF production allows the use of thalidomide
for treating inflammatory conditions, where it is desirable
to reduce TNF levels.
To further our understanding of thalidomide’s molecu-
lar mechanisms, we sought to explore the inflammation-
suppressive effect of this drug on gene expression by
using DNA microarrays in peripheral blood mono-
nuclear cells (PBMC) stimulated with LPS as a model of
inflammation.
Analysis of the molecular mechanisms of gene action
can be achieved using DNA microarrays, which allows
for the investigation of thousands of genes in a single ex-
periment. Although advantageous, the use of microar-
rays presents some difficulties related to data analysis,
including problems related to experimental noise, differ-
ences in dye incorporation and, in addition, the large
number of genes to be statistically tested [14-17]. Differ-
ent analytical approaches have been proposed to identify
gene expression profiles, but no method has shown
marked superiority over any other.
To identify genes associated with thalidomide treat-
ment, we propose a two-stage procedure for microarray
analysis. In the first stage, we use the rank product (RP)
method of BREITLING et al. [18] on the residual term
of the normalized LPS experiment with a less stringent
statistical criteria to identify a list of genes responding to
LPS stimulus. In the second stage, this set of genes was
analyzed to identify a subset of expressed genes in the
LPS stimulated cells treated with thalidomide.Results
Microarray pre-processing
In most microarray experiments, the general assumption
is that most of the genes will not be differentially
expressed; therefore, the MA-plot should be evenly dis-
tributed around zero for all values of A. However, due to
expected systematic biases in dye coupling, imbalances in
hybridization efficiencies and other technical biases, the
MA-plot may show the presence of these artifacts. The
MA-plot is a plot of the Cy5 (R) versus Cy3 (G) obtained
by plotting the intensity ratio M ¼ log2 Rð Þ  log2 Gð Þ by
the average intensity A ¼ log2 Rð Þ þ log2 Gð Þ½ =2 . The
graph for the LPS experiment is depicted in Figure 1. The
raw intensity data show a non-linear pattern in the MA-
plot. Figure 1a and 1b show the raw data for one slide of
each condition, LPS and LPS+ thalidomide. For each
slide, we applied the intensity global lowess regression ap-
proach for normalization and variability reduction of the
data within the slides. The use of this transformation was
efficient for properly removing the intensity dependent
curvature present in the data, and the method scaled and
centered each array (Figure 1c and 1d). Additional file 1:
Figure A.1 and Additional file 2: Figure A.2 shows the
MA plot for all arrays before and after lowess within
normalization.
After the within normalization, we normalized the ex-
pression values to achieve consistency between arrays
using the ANOVA model approach. The lowess centra-
lized the data for the two channels in each array, but for
further analysis to recognize differentially expressed
genes, it is recommended that all arrays have a common
reference level. This common reference level is obtained
with the residual term r of the ANOVA model, which is
the data used in the rank product method. See Add-
itional file 3: Figure B.1 (a) Box plot after lowess trans-
formation showing the centralization of the data for the
two channels; (b) Box plot of the residual term of the
ANOVA modeling.
The reproducibility of the arrays was evaluate by com-
puting the Pearson correlation coefficient between the
replicates within each array and between the probes
among the arrays. The r-values for within array varies
from 0.75 to 0.88 and between arrays from 0.25 to 0.65.
See Additional file 4: Table A.1 shows the correlations
for within arrays and table A.2 for the correlations be-
tween arrays.
Expressed genes and their functional classes under
LPS stimulation
After preprocessing the LPS arrays, the fold changes for
the genes ranged from 0.016 to 9.25. The median fold
change was 0.99, and about 50 % of the genes showed
values twice or greater than the median value. Using the
rank product statistics [18] we identify 1584 genes for





















































































Figure 1 MA-plots for one slide of each experimental condition. (a) LPS and (b) LPS + Thalidomide before lowess transformation, (c) and (d)
show the result of removing the intensity dependent curvature.
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nominal p-value threshold of 0.05. We did not control
for multiple tests because we had only three arrays,
which results in higher false discovery rates, and our
main interest was in eliminating non-significant differen-
tially expressed genes for the second stage of the ana-
lysis. Of the selected genes responding to LPS stimulus
in our experiment, after a literature search, we found
that 50 were also reported by SHARIF et al. [19], who
analyzed the expression of NF-κB in macrophages in re-
sponse to LPS using DNA microarrays of approximately
500 genes. Another six genes were reported by LEE
et al. [20] who analyzed the expression profile of neutro-
phils obtained from skin biopsy material from patients
with erythema nodosum leprosy. See additional file 5:
Table B.1 shows the genes that were common to these
two other studies focusing on LPS action.
To gain biological insights into the selected genes, a
functional analysis was performed by searching for asso-
ciations with Gene Ontology (GO) annotations to clas-
sify the genes altered by the LPS treatment into known
functional processes. The gene universe was obtained by
removing from the whole assayed genes those without
GO representation, following the recommended proced-
ure for using GOstats [21]. For the set of selected genes,
the program finds the number of each GO term and
counts the number of appearances of the term in the set
of assayed genes in the experiment that have EntrezGene identifiers or that map to available GO terms. A p-
value for each GO term is computed indicating the
probability that this term is randomly selected. There-
fore, the GO terms with the lowest p-values are the ones
most specific for the analyzed genes. Table 1 shows the
biological process in differentially expressed genes in the
LPS data obtained by selecting the GO categories with
p-value< 0.05.
The analyses showed the biological process regulation
of important classes such as the regulation of T-helper
cell differentiation, the negative regulation of blood co-
agulation, the regulation of coagulation, alpha-beta T cell
activation involved in immune responses, T cell differen-
tiation involved in immune responses, CD4-positive,
alpha-beta T cell differentiation involved in immune
responses, cell chemotaxis, and positive regulation of
receptor-mediated endocytosis terms that are related to
an inflammatory/immune response induced by LPS. Be-
sides these, other terms were also found altered by LPS,
such as smooth muscle adaptation nerve development,
intracellular cholesterol transport, and intracellular lipid
transport.
Analysis of cellular components (parts of the cell or
extra cellular environment) revealed several genes in the
cytosol component (GO: 0005829), with 158 expressed
genes, where 82 genes are over-expressed. Another cellu-
lar component that showed the greatest number of genes
was non-membrane-enclosed organelles (GO: 0043228),
Table 1 Identification of LPS affected biological processes using the GOstats/R package for gene ontology analysis
GOBPID Pvalue Count Size Term
GO:0006414 0.000 36 78 translational elongation
GO:0042274 0.000 7 8 ribosomal small subunit biogenesis
GO:0042254 0.000 10 20 ribosome biogenesis
GO:0051591 0.001 6 9 response to cAMP
GO:0042416 0.004 3 3 dopamine biosynthetic process
GO:0050818 0.004 10 26 regulation of coagulation
GO:0015711 0.005 10 27 organic anion transport
GO:0032365 0.007 4 6 intracellular lipid transport
GO:0030195 0.007 8 20 negative regulation of blood coagulation
GO:0045730 0.011 5 10 respiratory burst
GO:0045022 0.013 3 4 early endosome to late endosome transport
GO:0014805 0.013 3 4 smooth muscle adaptation
GO:0032367 0.013 3 4 intracellular cholesterol transport
GO:0045410 0.013 3 4 positive regulation of interleukin-6 biosynthetic process
GO:0060325 0.013 3 4 face morphogenesis
GO:0030198 0.014 13 44 extracellular matrix organization
GO:0002293 0.014 4 7 alpha-beta T cell differentiation during immune response
GO:0042093 0.014 4 7 T-helper cell differentiation
GO:0045980 0.014 4 7 negative regulation of nucleotide metabolic process
GO:0006323 0.017 13 45 DNA packaging
GO:0030595 0.017 9 27 leukocyte chemotaxis
GO:0006333 0.017 14 50 chromatin assembly or disassembly
GO:0046635 0.018 5 11 positive regulation of alpha-beta T cell activation
GO:0045732 0.020 7 19 positive regulation of protein catabolic process
GO:0033993 0.024 4 8 response to lipid
GO:0002318 0.024 2 2 myeloid progenitor cell differentiation
GO:0002523 0.024 2 2 leukocyte migration during inflammatory response
GO:0008588 0.024 2 2 release of cytoplasmic sequestered NF-kappaB
GO:0015808 0.024 2 2 L-alanine transport
GO:0015824 0.024 2 2 proline transport
GO:0018347 0.024 2 2 protein amino acid farnesylation
GO:0019614 0.024 2 2 catechol catabolic process
GO:0031440 0.024 2 2 regulation of mRNA 3'-end processing
GO:0032417 0.024 2 2 positive regulation of sodium:hydrogen antiporter activity
GO:0032510 0.024 2 2 endosome to lysosome transport via multivesicular body sorting pathway
GO:0033625 0.024 2 2 positive regulation of integrin activation
GO:0033630 0.024 2 2 positive regulation of cell adhesion mediated by integrin
GO:0034109 0.024 2 2 homotypic cell-cell adhesion
GO:0042420 0.024 2 2 dopamine catabolic process
GO:0042832 0.024 2 2 defense response to protozoan
GO:0043179 0.024 2 2 rhythmic excitation
GO:0045627 0.024 2 2 positive regulation of T-helper 1 cell differentiation
GO:0045628 0.024 2 2 regulation of T-helper 2 cell differentiation
GO:0048103 0.024 2 2 somatic stem cell division
GO:0048539 0.024 2 2 bone marrow development
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over-expressed genes. In the category molecular function
(the elemental activities of the gene product at the mo-
lecular level), the over-represented profiles corresponded
to categories of GTPase regulator activity (GO: 0030695),
with a total of 41 genes in the profile, where 25 are over-
expressed, and there was enzyme regulator activity with
88 genes in the profile (52 genes over-expressed).
While GO annotations can summarize and simplify the
interpretation of the selected genes, additional enrichment
analysis for these genes can be gained by identifying meta-
bolic pathways in the Kyoto Encyclopedia of Genes and
Genomes (KEGG). For this analysis, we also used the
GOstats package, and the cut-off was p< 0.05 as well.
Table 2 shows the enriched metabolic pathways identified
from the KEGG database. From this analysis, for the over-
represented KEGG pathways, it is possible to observe sev-
eral genes identified in the ribosome pathway (hsa03010)
and the glutathione metabolism pathway (hsa00480), with
32 genes and 10 genes, respectively, in addition to fruc-
tose and mannose metabolism pathways, DNA replica-
tion, phototransduction, and ABC transporters.
The analysis of LPS activated cultures led to the iden-
tification of genes involved in processes or pathways
related to inflammation. This provides a more specific
analytic set of genes for studying the mechanism of ac-
tion of thalidomide in inflammation because only those
genes related to inflammation are considered.
Modulation of LPS induced genes by thalidomide
Only genes selected in the LPS experiment were taken
into account for further analysis involving the identifica-
tion of genes that were altered when treated with thal-
idomide. In this case, the gene expression values were
again log-transformed before preprocessing with lowess
and ANOVA following a similar approach as described
for the LPS data set. After these preprocessing stages,
the LPS + thalidomide residual data had a range of fold
changes for the three arrays varying from 0.016 to 9.25.
Rank product analysis was used to obtain a subset of 64
genes altered by the action of thalidomide (Table 3)
using a cutoff nominal p-value of 0.001. Again, we did
not considered multiple test correction due to the small
sample size. Here, we used a more stringent cutoff levelTable 2 Identification of biological pathways via KEGG
for LPS
KEGGID Pvalue Count Size Term
3010 0.000 30 62 Ribosome
51 0.018 9 27 Fructose and mannose metabolism
3030 0.032 8 25 DNA replication
480 0.038 10 35 Glutathione metabolism
2010 0.040 8 26 ABC transportersbecause we are more interested in reducing the occur-
rence of type I error (false positive) due to the possibility
of coordinated expression of genes in the inflammation
model. For the selection of genes related to the inflam-
mation process, the presence of false positive genes was
not critical. The importance here was to avoid the pres-
ence of genes with coordinated expression, since the RP
method assumes the independence of genes and may
lead to underestimation when the values of the expres-
sion of many genes at the top of the list are dependent.
We examined whether the selected genes under a thal-
idomide treatment share similar biological functions or
are within similar functional classes and pathways of the
LPS experiment using GOstats. Analysis of the associ-
ation between gene and class in the category of bio-
logical process gene ontology identified terms that were
more significant within the group (Table 4). The associ-
ation analysis using the gene-class KEGG also identified
pathways that may be changed by thalidomide (Table 5).
Evaluation of gene expression by RT-PCR
For these experiments, PBMC from 4 healthy donors
were cultured and stimulated as described above. RNA
was isolated from the cultures, reverse transcribed and
expression of five genes was assayed by real time PCR.
Three of them (EPHX1, UBE2O, PTX3) were down regu-
lated (4–5 fold reduction) in cells treated with thalido-
mide whereas other two genes, FTH1 and IDH1, were
up regulated (Figure 2) when compared to cultures sti-
mulated with LPS alone. These data are in agreement
with the microarray analysis.
Discussion
Despite the recognized clinical merits of thalidomide,
the molecular mechanism of the action of this drug still
remains unclear. Over the past 10 years, even in the face
of increasing development of microarray technology to
study gene expression profiles, there is a limited amount
of microarray data related to thalidomide, and most
studies focus on the use of this drug in different types of
cancers [22-24]. Therefore, this study was undertaken to
understand the mechanism of action of thalidomide in
the inhibition of inflammatory processes.
In this paper, we describe a two-stage framework. In the
first stage, we identified a set of differentially expressed
genes in a model of inflammation induced by lipopolysac-
charide. The analysis of this experiment identified 1584
genes that may be altered by the inflammatory process.
We used a cutoff nominal p-value of 0.05 during this first
stage to avoid possible missing genes that, even with low
fold changes, may be induced by the action of thalido-
mide. Therefore, we increase the chance to have larger
numbers of false positives in the subset of selected genes
during this first stage since in the second stage of analysis,
Table 3 Genes with altered expression due to thalidomide action
Down regulated genes Up-regulated genes
Acc. Number Symbol FC P value Acc. Number Symbol FC P value
NM_022052 NXF3 0.39 0.0000 XM_030485 2.98 0.0000
NM_003192 TBCC 0.53 0.0000 NM_017660 p66alpha 2.91 0.0000
NM_020346 SLC17A6 0.54 0.0001 NM_000994 RPL32 2.18 0.0000
NM_000120 EPHX1 0.62 0.0002 NM_002032 FTH1 2.25 0.0000
NM_004081 DAZ4 0.62 0.0002 NM_001028 RPS25 2.16 0.0000
NM_002069 GNAI1 0.63 0.0003 NM_033496 HK1 2.21 0.0001
NM_022066 E2-230 K 0.53 0.0003 AF245436 FLJ23518 2.10 0.0001
NM_006468 POLR3C 0.63 0.0005 NM_024552 LASS4 2.01 0.0002
NM_018230 NUP133 0.56 0.0006 NM_023071 SPATS2 1.98 0.0004
NM_000303 PMM2 0.62 0.0007 NM_015937 PIGT 1.95 0.0004
NM_001868 CPA1 0.65 0.0008 NM_005896 IDH1 1.69 0.0005
NM_022163 MRPL46 0.63 0.0008 NM_006995 BTN2A2 1.68 0.0006
AF113016 PRO1073 0.57 0.0008 NM_003690 PRKRA 1.79 0.0009
NM_017708 FLJ20200 0.62 0.0009 NM_016025 DREV1 2.06 0.0009
NM_021737 CLCN6 0.66 0.0009 NM_021734 SLC25A19 1.75 0.0009
NM_002852 PTX3 0.69 0.0011 NM_022663 CTAGE1 1.76 0.0009
NM_000042 APOH 0.67 0.0011 NM_019848 SLC10A3 1.90 0.0010
NM_006052 DSCR3 0.67 0.0014 NM_022126 LHPP 1.71 0.0011
XM_007829 0.68 0.0017 NM_001493 GDI1 1.69 0.0012
NM_002630 PGC 0.67 0.0018 BC003599 BM-009 1.57 0.0013
NM_003033 SIAT4A 0.68 0.0019 NM_001825 CKMT2 1.83 0.0014
NM_001146 ANGPT1 0.68 0.0020 NM_013243 SCG3 1.83 0.0017
NM_014872 ZBTB5 0.69 0.0022 NM_005505 SCARB1 1.59 0.0018
NM_002819 PTBP1 0.66 0.0023 NM_024841 FLJ14213 1.61 0.0019
NM_024076 KCTD15 0.70 0.0024 NM_005557 KRT16 1.55 0.0022
NM_001586 CXorf2 0.68 0.0025 NM_003205 TCF12 1.56 0.0025
NM_017777 FLJ20345 0.70 0.0025 NM_003652 CPZ 1.58 0.0026
NM_003626 PPFIA1 0.71 0.0028 NM_001012 RPS8 1.55 0.0026
NM_006858 IL1RL1LG 0.70 0.0032 NM_001003 RPLP1 1.51 0.0027
NM_033540 MFN1 0.71 0.0046 NM_004576 PPP2R2B 1.56 0.0027
NM_004202 TMSB4Y 1.55 0.0030
NM_001626 AKT2 1.50 0.0030
NM_001152 SLC25A5 1.57 0.0030
NM_017452 STAU 1.59 0.0037
NM_000576 IL1B 1.59 0.0049
The table shows the accession number (Acc. number), the gene symbol, the fold-change (FC) and the Pvalue.
Table 4 Identification of biological processes using gene ontology affected by the action of thalidomide
GOBPID Pvalue Count Size Term
GO:0015931 0.006 3 9 nucleobase, nucleoside, nucleotide and nucleic acid transport
GO:0045429 0.011 2 4 positive regulation of nitric oxide biosynthetic process
GO:0051168 0.011 2 4 nuclear export
GO:0044267 0.017 18 246 cellular protein metabolic process
GO:0051707 0.022 3 14 response to other organism
GO:0046209 0.027 2 6 nitric oxide metabolic process
GO:0048514 0.032 3 16 blood vessel morphogenesis
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Table 5 KEEG enrichment and thalidomide
KEGGID Pvalue Count Size Term
4530 0.011 3 11 Tight junction
533 0.046 1 1 Keratan sulfate biosynthesis
604 0.046 1 1 Glycosphingolipid biosynthesis - ganglio series
1031 0.047 2 8 Glycan structures - biosynthesis 2
4620 0.047 2 8 Toll-like receptor signaling pathway
51 0.059 2 9 Fructose and mannose metabolism
4210 0.059 2 9 Apoptosis
3010 0.064 3 21 Ribosome
52 0.089 1 2 Galactose metabolism
512 0.089 1 2 O-Glycan biosynthesis
720 0.089 1 2 Reductive carboxylate cycle (CO2 fixation)
5213 0.089 1 2 Endometrial cancer
5218 0.089 1 2 Melanoma
5223 0.089 1 2 Non-small cell lung cancer
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ond stage, the analysis of the experiment with thalido-
mide identified 64 differentially expressed genes, among
which 30 were under-expressed genes and 34 over-
expressed genes.
In this study, we used the rank product method as a
basic tool for identifying differentially expressed genes.
This method is based on the ratio of expression, where
mRNA levels are compared under different conditions
(A and B) on a slide. It is an approach that allows for an
easier interpretation of the results. Use of the rank prod-
uct method has been recommended after appropriate
normalization for situations where there are few repli-
cates [25]. The raw data showed systematic deviations
that were removed using normalization techniques.
Using the logarithmic transformation, the ratios between
the two channels are expressed in terms of differences,
and it stabilizes the variance of the wells of high inten-
sity. After the logarithmic transformation, the data
showed characteristic intensity dependence and, as a re-
sult, were normalized using the lowess method. This
method of local regression curve fitting reduced the
variability dependent on the intensity, allowing biological
differences to be better visualized. Finally, the ANOVA
provided a method to normalize between arrays and the
residue from this fitting is used as the data for the rank
product method.
The list of genes identified as differentially expressed
in the experiment with thalidomide can provide infor-
mation about the mechanism of action of this drug.
However, obtaining this list is not enough to provide in-
formation related to the biological mechanisms involved
on these altered profiles. To help the interpretation of
the data, we apply techniques of gene ontology analysis
that are freely available to categorize the differentiallyexpressed genes according to functional processes. We
also used pathway analysis for the identification of meta-
bolic pathways altered, providing further information
regarding the mechanisms of action of thalidomide.
The enrichment analysis allowed the identification of
biological processes affected by thalidomide. Among
these processes, we identified the morphogenesis of blood
vessels that may explain the anti-angiogenic properties of
thalidomide, with angiopoietin 1 (ANGPT1) identified as
under-expressed. The protein encoded by this gene is a
secreted glycoprotein that activates the receptor, inducing
its phosphorylation. This protein plays a key role in medi-
ating reciprocal interactions between the endothelium
and the underlying matrix as well as in the mesenchyme.
The protein also contributes to the stabilization and mat-
uration of blood vessels and may be involved in the initial
development of the heart [26]. In addition, other genes
were identified that are involved in apoptosis mechanisms
and in signaling pathways, such as the polypeptide pro-
tein tyrosine phosphatase, the receptor type F (PTPRF), a
member of the protein phosphatase family that regulate a
variety of cellular processes including cell growth, differ-
entiation, mitotic cycle, and oncogenic transformation
[27,28]; the interferon inducible double stranded RNA
dependent activator (PRKRA), which encodes a protein
kinase that mediates the effects of interferon in response
to viral infection [29].
Among the genes validated by RT-PCR, UBE2O is an
E2 ubiquitin ligase, it has a role in regulating protein
degradation [30]. Pentraxin-3, PTX3, belongs to the
acute phase proteins family produced mainly by macro-
phages, dendritic cells and endothelial cells in response
Toll-like receptor ligands and inflammatory cytokines
(eg. TNF and IL-1β) [31]; Ferritin, heavy polypeptide 1







Figure 2 Thalidomide modulates gene expression induced by LPS in vitro. PBMC obtained from healthy donors were pre-treated with
thalidomide (30 min) and stimulated or not (NS) with LPS (1μg/mL) for 3 h. As an additional control, non-stimulated cells were also maintained in
culture with DMSO alone (0.1 %). Results are mean± SEM of four independent experiments carried out in duplicate. Expression of genes induced
by LPS, EPHX1, E2-230 K and PTX3 were down regulated In the presence of thalidomide whereas FTH1 and IDH1 were upregulated. Statistical
differences between groups were determined via a one-way analysis of variance (ANOVA) followed by the Bonferroni’s multiple comparison post-
test: *p< 0.05; **p< 0.01 indicate significant differences when compared to cultures stimulated with LPS alone.
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wide range of physiologic processes. Recently it was
described the interaction of FTH1 to the pathway Fas-
Daxx-ASK1-JNK1, demonstrating its properties to in-
hibit apoptosis mediated by Daxx and inhibition of JNK
activation [32]. The raise of FTH1 gene expression by
thalidomide can also imply in the immunomodulationactivity of this drug due to possible FTH1 inhibition of
JNK activation. EPHX1 encodes the gene of epoxide
hydrolase 1, it biotransforms epoxide derivatives of phar-
maceuticals, including metabolites of certain antiepilep-
tic medications [33].
Thalidomide had the ability to induce IDH1 gene ex-
pression, Isocitrate dehydrogenase (IDH)-1 mutations
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in arginine 132 result in a new ability of the enzyme to
catalyse the NADPH-dependent reduction of alpha-
ketoglutarate to R(−)-2-hydroxyglutarate (2HG) [34].
The biological processes of the genes altered by the LPS
inflammation model, which were affected by thalidomide,
are processes related to angiogenesis and to the response
to metabolic stress; a microorganism could for example,
trigger these processes. No direct action of thalidomide
on the gene expression of inflammatory cytokines was
observed, but thalidomide’s action occurs through pre-
cursor processes of the inflammation. A similar result
was recently reported by NOMAN et al. [35] in a study
of the inhibition of TNF production in RAW 264.7 cells.
In that work, the authors show that thalidomide has an
indirect effect on LPS signaling via down-regulation of
the MyD88 protein. This universal adapter protein is
used by all Toll-Like Receptors (except TLR3) to activate
the transcription factor NF- κB and mRNA and inhibits
LPS-induced TNF production.
Conclusions
In conclusion, we carried out a two-stage procedure of
microarray analysis to detect genes associated with thal-
idomide treatment under an inflammation model. The
proposed method detected effects that may fail to emerge
using a single experiment with LPS and thalidomide. To
find statistically significant changes in gene expression
with our small data set, we used the rank product method,
which is a flexible technique for detecting differentially
expressed genes, even under adverse conditions such as
with restricted replications [25]. Of the 64 identified
genes, five were evaluated using real time PCR to provide




Lipopolysacharide (LPS) from Salmonella Minnesota Re
595 was purchased from Sigma Chemical Co. (St. Louis,
MO). Thalidomide was obtained from Calbiochem
(Cambridge, MA); DMSO (Sigma) was used as a solvent
for thalidomide and the final concentration of DMSO in
the cell cultures was 0.1 %.
Cell culture and stimulation
Buffy coats were obtained from three healthy donors at
the Hemotherapy Service of the Clementino Fraga Filho
University Hospital, associated with the Federal University
of Rio de Janeiro, RJ, Brazil, in accordance with the guide-
lines set down in the Declaration of Helsinki. The acquisi-
tion of all specimens was approved by the Human Ethics
Committee of the Oswaldo Cruz Foundation, Brazil.Isolation of peripheral blood mononuclear cells (PBMC)
was performed under endotoxin free conditions through
Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway,
NJ) density centrifugation. Cells (5x106/well) were cul-
tured in 6-well plates (Costar Corporation, Cambridge,
MA), in RPMI 1640 medium supplemented with 100U/ml
penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine,
and 10 % FCS (Gibco BRL, Gaithersburg, MD) at 37 °C.
Cultures were pre-treated or not with thalidomide (25 μg/
ml) or were left unstimulated or were stimulated with LPS
(1 μg/ml) for an additional 3 hour. After the stimulation
period, cells were recovered and lysed for RNA isolation
by using tryzol (Gibco, BRL), processed according to the
manufacturer’s recommendation. The experiments con-
sidered a pool of RNAs obtained for each experimental
condition (non-stimulated untreated cells; cells stimulated
with LPS alone; cells treated with thalidomide alone; cells
treated with LPS and thalidomide).
Microarray
The microarray data were obtained through a partner-
ship between the Institute of Biophysics Carlos Chagas
Filho (UFRJ), the Leprosy Laboratory, FIOCRUZ and the
DNA Microarray Facility at the Universidad Nacional
Autónoma de México (UNAM - Mexico). Oligonucleo-
tides (50 mer) representing 9984 human genes, pur-
chased by UNAM from the MWG Biotech Company
(www.mwg-biotech.com), were spotted in duplicate onto
superamine-coated glass slides (Telechem International)
using the Virtek ChipWriter, resulting in a total of
19,968 spots. For each treatment condition, when we
compared LPS, thalidomide or LPS + thalidomide, target
cDNA was hybridized to three microarrays. To reduce
the bias of intensity associated with the difference in dye
incorporation, for two arrays, the stimulated samples
(LPS, thalidomide or LPS+ thalidomide) were labeled
using red-fluorescent dye, Cy5, and the non-exposed sam-
ples were assigned to the green-fluorescent dye, Cy3. For
the third array, dye labeling was reversed. The experimen-
tal microarray design used here is known as “dye swap.”
After standard pre-hybridization for 1 h at 420 C, samples
taken from the untreated cells (control) and treated cells
were added to buffer hybridization Hybit 2 (Telechea
International), and they were hybridized overnight in each
array at 420 C in a humidified chamber (Corning). The
hybridized slides were then washed, dried and scanned
using the Scan Array 4000 (Packard Biochips).
The intensities of the spots for each array were obtained
with the Array Pro Analyzer software, which generates
two 16 bit images, one for each dye. For each array, the
values of the gene expression were obtained by subtracting
for each spot its averaged background from the mean
foreground value. For cases with resulting values less than
or equal to zero, we replaced them with the internal
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gene was eliminated. After background correction, the
mean values of the replicates were used to obtain the loga-
rithm with base two, resulting in the expression level yijkg
for each array. Initial analysis involved the production of
MA-plots for the arrays (Figure 1).
This exploratory tool is useful to identify systematic
variations due to different dye labeling efficiencies, dif-
ferences in the concentration of DNA on arrays, and
other effects. The MA-plot reveals whether the data ex-
hibit an intensity-dependent structure. The presence of
systematic effects impairs a proper analysis of individual
slides. Comparison of expression levels between slides
show a non-linear pattern in the MA-plot, indicating
the use of data normalization to remove these effects.
Here, we used lowess, a locally weighted scatter plot
smoothing for within slide normalization and variability
reduction [36].
The use of this transformation is efficient to properly
scale and to center the data for each slide. For proper
comparison between arrays, it is still necessary to center
all arrays at zero, and this task has been achieved with
the use of the ANOVA model [37]. The ANOVA model
was used only for normalization between slides. The
model considered the sources of variability that are usu-
ally present in a microarray experiment, and is defined
for each gene g as:
yijkg ¼ μþ Ai þ Dj þ ADij þ rijkg
where A and D are the array i, and the dye effects, j. AD
is the interaction between dye and array and μ captures
the array global mean for all genes, g, and the experi-
mental condition is k. The r term accounts for unex-
plained factors and is assumed as the error term with
zero mean. This residue from the ANOVA model was
used as the main data for statistical analysis using the
non-parametric rank product statistics [18] to identify
differentially expressed genes.
The entire normalization process, using the lowess
transformation and normalization with the ANOVA
model, was done with the package MAANOVA/R [38].
This preprocessing stage reduced or eliminated the vari-
ability introduced by differences in the efficiency of dye
incorporation and the differences in experimental condi-
tions that may influence the intensity of hybridization.
To carry out the rank product analysis, we used the Bio-
conductor R/Rank Prod package [39].
The rank product (RP) approach was selected because
it is a nonparametric test and does not require stringent
assumptions of probability distributions. It is also a
method that is less prone to be influenced by experimen-
tal noise, being applicable to experiments with a small
number of arrays [25], as in our case, in which there wereonly three arrays for each experimental condition. The
RP method is based on rank ordering the fold change of
the genes for each array, followed by computing a geo-
metric mean of the ranks. Converting the fold changes
into ranks provides a more robust measure across arrays
even with a poor correlation across platforms. Genes
associated with the smallest ranks are the ones that
should be marked for further consideration. The RP
computed values is evaluated against a sampling distri-
bution obtained using permutation to generate nominal
p-values and also false discovery rates. A list of up- or
down- expressed genes can be obtained using a chosen
threshold level. Here we use the nominal p-values for the
ranked genes.
To further our understanding of the thalidomide mech-
anism of action, as a first step, we considered the LPS in-
fection model and we identified a list of up- or down
regulated genes using a less stringent p-value so that a lar-
ger number of genes would be selected as altered by the
LPS inflammation effect. The lists of selected differen-
tially expressed genes in response to LPS were submitted
to a functional analysis based on its association to Gene
Ontology (GO) terms. This enrichment analysis allowed
an integrated information of biological processes altered
by LPS. Association between the genes and their classes,
as defined in the databases of Gene Ontology (Gene
Ontology) and KEGG pathways (Encyclopedia of Genes
and Genomes Kyoto), was evaluated using the hypergeo-
metric test available in GOstats [21], a Bioconductor
package written in R. Additionally, we did a literature
search to identify reported altered genes under LPS
stimulus that are common to our selected set.
The set of genes selected in this first stage of analysis
was then investigated in the LPS + thalidomide experi-
ments. It is worth noting that all methods used for the
LPS experiment were also applied for the identification
of differentially expressed genes within this experiment.
Real time PCR
For validation of the microarray results, PBMC obtained
from 4 healthy donors were cultured and stimulated under
the same conditions as described above. Cells were pre-
treated or not with thalidomide (30 min), and stimulated
with LPS 1ug/ml for 3 h, when total RNA was extracted
by using Trizol. For RT-PCR, 1μg of total RNA was re-
verse transcribed using oligo-dT primers (Life Technolo-
gies) and the resulting cDNA was amplified by Real time
RT-PCR using the ABI 7500 Sequencer and the Taqman
expression assays (Applied Biosystems). For detection of
genes, primers used were: EPHX1 Hs01116806_m1,
UBE2O Hs00222904_m1, PTX3 Hs00173615_m1, FTH1
Hs01694011_s1, IDH1 Hs00271858_m1. GAPDH was used
as normalization control. The data were analyzed using
the 2-ΔΔCT method.
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